Randomized Study Comparing Electronic Patient Reported Outcomes(ePROs) Monitoring with Routine Follow Up During Trastuzumab Deruxtecan Treatment for Inoperable or Metastatic Breast Cancer Patients (PRO-DUCE study)
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PRO-DUCE study
Most Recent Events
- 22 May 2025 According to Daiichi Sankyo Company media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology Scientific Program (#ASCO25)
- 18 Feb 2022 New trial record
- 10 Dec 2021 Trial design presented at the 44th Annual San Antonio Breast Cancer Symposium